Fusidic acid, cutaneous

Generic name
Fusidic acid, cutaneous
Brand name
ATC Code
D06AX01
Compare …

Fusidic acid, cutaneous

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

The systemic uptake of fusidic acid after topical administration to intact skin is low [Turnidge 1999].

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Superficial primary skin infections caused primarily by staphylococci
  • Cutaneous
    • 0 years up to 18 years

      • 2%: apply to the affected skin 3 times daily.
        Less frequent application may be sufficient if the lesion is covered.

      • Duration of treatment:

        Until healing is achieved or a maximum of 14 days

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ANTIBIOTICS FOR TOPICAL USE

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Other antibiotics for topical use
D06AX09

References

  1. Koning S, et al, Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial., BMJ, 2002, Jan 26;324(7331), 203-6
  2. Oranje AP, et al, Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study, Dermatology, 2007, 215(4), 331-40
  3. George A, et al, A systematic review and meta-analysis of treatments for impetigo, Br J Gen Pract, 2003, Jun;53(491), 480-7
  4. Turnidge J., Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics, Int J Antimicrob Agents, 1999, Aug;12 Suppl 2:, S23-34
  5. White DG, et al, Topical antibiotics in the treatment of superficial skin infections in general practice--a comparison of mupirocin with sodium fusidate, J Infect, 1989, May;18(3), 221-9
  6. Koning S, et al, Interventions for impetigo, Cochrane Database Syst Rev, 2004, (2), CD003261
  7. NHG, NHG Standaard Bacteriele huidinfecties, Augustus 2007, http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M68_svk.htm
  8. Will-Pharma B.V, SmPC Afussine (RVG 111682) 22-04-2022, www.geneesmiddeleninformatiebank.nl

Changes

Therapeutic Drug Monitoring


Overdose